Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
INSIGHT: ripretinib versus sunitinib in previously treated KIT exon 11 plus exon 17/18 mutant advanced GIST
2022-503058-37-00Phase 3Authorised
- Sponsor
- Deciphera Pharmaceuticals
- Start
- Nov 2023
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
- Countries
- 16
01
Overview
Phase 3, randomised, open-label trial in gastrointestinal stromal tumor (GIST) comparing Ripretinib with Sunitinib (2 arms). Primary endpoint: Progression-free survival by independent radiologic review per mRECIST. Planned start Nov 2023; status: authorised.
02
Drugs
ripretinibsunitinib
03
Conditions
gastrointestinal stromal tumor (GIST)
Beyond the preview
Go deeper on 2022-503058-37-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-503058-37-00.